Aflatoxin B1 metabolism (WP1262)
Mus musculus
Aflatoxins are naturally occurring mycotoxins that are produced by many species of Aspergillus, a fungus, most notably Aspergillus flavus and Aspergillus parasiticus. After entering the body, aflatoxins are metabolized by the liver to a reactive intermediate, aflatoxin M1, an epoxide. Aflatoxin B1 is considered the most toxic and is produced by both Aspergillus flavus and Aspergillus parasiticus. Source: Wikipedia
For a description of pathway objects, see the WikiPathways Legend.
Authors
Thomas Kelder , Kristina Hanspers , Christine Chichester , and Martina Summer-KutmonActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
- Hepatic transcriptome implications for palm fruit juice deterrence of type 2 diabetes mellitus in young male Nile rats (2016).
- Proteomic profiling of salivary gland after nonviral gene transfer mediated by conventional plasmids and minicircles (2014).
- GeneSetCart: assembling, augmenting, combining, visualizing, and analyzing gene sets (2025).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Mus musculusCommunities
Annotations
Pathway Ontology
aflatoxin metabolic pathwayLabel | Type | Compact URI | Comment |
---|---|---|---|
Aflatoxin B1 exo-8,9-epoxide-GSH | Metabolite | pubchem.compound:5460816 | |
aflatoxin B1 | Metabolite | hmdb:HMDB0006552 | |
Aflatoxin B1 exo-8,9-epoxide | Metabolite | hmdb:HMDB0006558 | |
Aflatoxin M1 | Metabolite | pubchem.compound:15558498 | |
Aflatoxin Q1 | Metabolite | pubchem.compound:104757 | |
Akr7a5 | GeneProduct | ensembl:ENSMUSG00000028743 | |
Cyp1a2 | GeneProduct | ensembl:ENSMUSG00000032310 | |
Gstt1 | GeneProduct | ensembl:ENSMUSG00000001663 | |
Gstm1 | GeneProduct | ncbigene:14862 | |
Ephx1 | GeneProduct | ensembl:ENSMUSG00000038776 |
References
- Glutathione S-transferase-catalyzed conjugation of bioactivated aflatoxin B(1) in human lung: differential cellular distribution and lack of significance of the GSTM1 genetic polymorphism. Stewart RK, Smith GB, Donnelly PJ, Reid KR, Petsikas D, Conlan AA, et al. Carcinogenesis. 1999 Oct;20(10):1971–7. PubMed Europe PMC Scholia
- Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. Guengerich FP, Cai H, McMahon M, Hayes JD, Sutter TR, Groopman JD, et al. Chem Res Toxicol. 2001 Jun;14(6):727–37. PubMed Europe PMC Scholia
- Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Tiemersma EW, Omer RE, Bunschoten A, van’t Veer P, Kok FJ, Idris MO, et al. Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):785–91. PubMed Europe PMC Scholia
- Reaction of aflatoxin B(1) oxidation products with lysine. Guengerich FP, Arneson KO, Williams KM, Deng Z, Harris TM. Chem Res Toxicol. 2002 Jun;15(6):780–92. PubMed Europe PMC Scholia
- Translational strategies for cancer prevention in liver. Kensler TW, Qian GS, Chen JG, Groopman JD. Nat Rev Cancer. 2003 May;3(5):321–9. PubMed Europe PMC Scholia
- Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. He XY, Tang L, Wang SL, Cai QS, Wang JS, Hong JY. Int J Cancer. 2006 Jun 1;118(11):2665–71. PubMed Europe PMC Scholia
- Cytochrome P450s and other enzymes in drug metabolism and toxicity. Guengerich FP. AAPS J. 2006 Mar 10;8(1):E101-11. PubMed Europe PMC Scholia
- CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, et al. Drug Metab Dispos. 2006 Oct;34(10):1672–6. PubMed Europe PMC Scholia
- Aldo-keto reductases and bioactivation/detoxication. Jin Y, Penning TM. Annu Rev Pharmacol Toxicol. 2007;47:263–92. PubMed Europe PMC Scholia
- The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Barski OA, Tipparaju SM, Bhatnagar A. Drug Metab Rev. 2008;40(4):553–624. PubMed Europe PMC Scholia